Single Chain Epidermal Growth Factor Receptor Antibody Conjugated Nanoparticles for in vivo Tumor Targeting and Imaging

• Type of Material: Article
• Authors: Lily Yang, Emory University; Hui Mao, Emory University; Y. Andrew Wang, Ocean Nanotech, LLC; Zehong Cao, Emory University; Xianghong Peng, Emory University; Xiaoxia Wang, Emory University; Hongwei Duan, Emory University; Chunchun Ni, Emory University; Qingan Yuan, Fox Chase Cancer Center; Gregory Adams, Fox Chase Cancer Center; Mark Q. Smith, Emory University; William C Wood, Emory University; Xiaohu Gao, University of Washington; Shuming Nie, Emory University
• Language: English
• Date: 2009-02
• Publisher: Wiley: 12 months
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: © 2009 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
• Final Published Version (URL): http://onlinelibrary.wiley.com/doi/10.1002/smll.200800714/abstract
• Title of Journal or Parent Work: Small
• ISSN: 1613-6810
• Volume: 5
• Issue: 2
• Start Page: 235
• End Page: 243
• Grant/Funding Information: This research project is supported by the Emory-Georgia Tech Nanotechnology Center for Personalized and Predictive Oncology of NIH, the NCI Center of Cancer Nanotechnology Excellence (CCNE, U54 CA119338-01), and in part by the Idea Award of the Breast Cancer Research Program of the Department of Defense (BC 021952), a seed grant from the Golfers Against Cancer, and the Nancy Panoz Endowed Chair (Dr. Lily Yang).
• Keywords: quantum dots; drug delivery; nanoparticles; proteins; antibodies
• Research Categories: Health Sciences, Oncology; Health Sciences, Radiology; Health Sciences, Medicine and Surgery

Abstract

Epidermal growth factor receptor (EGFR) targeted nanoparticle are developed by conjugating a single-chain anti-EGFR antibody (ScFvEGFR) to surface functionalized quantum dots (QDs) or magnetic iron oxide (IO) nanoparticles. The results show that ScFvEGFR can be successfully conjugated to the nanoparticles, resulting in compact ScFvEGFR nanoparticles that specifically bind to and are internalized by EGFR-expressing cancer cells, thereby producing a fluorescent signal or magnetic resonance imaging (MRI) contrast. In vivo tumor targeting and uptake of the nanoparticles in human cancer cells is demonstrated after systemic delivery of ScFvEGFR-QDs or ScFvEGFR-IO nanoparticles into an orthotopic pancreatic cancer model. Therefore, ScFvEGFR nanoparticles have potential to be used as a molecular-targeted in vivo tumor imaging agent. Efficient internalization of ScFvEGFR nanoparticles into tumor cells after systemic delivery suggests that the EGFR-targeted nanoparticles can also be used for the targeted delivery of therapeutic agents.